Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 plus ranibizumab dose-ranging study in wet age-related macular degeneration
2017-002698-20Phase 2Completed
- Sponsor
- Opthea Limited
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sozinibercept in exudative macular degeneration (3 arms), sponsored by Opthea Limited. Primary endpoint: Mean change from baseline in ETDRS BCVA letters at Week 24. Started Jan 2018; status: completed.
02
Drugs
sozinibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2017-002698-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002698-20.